We turn research and knowledge into products and services that benefit society

Inven2 10 year logo

Inven2 10th anniversary

Inven2 is 10 years in 2020.. ‘I’m proud of what we have achieved over these ten years. I’m particularly proud of the fact that we have contributed to ploughing NOK 500 million back into new research and innovation,’ says Ole Kristian Hjelstuen, CEO of Inven2.

Latest news

Latest news

Here you can read the latest news regarding Inven2s portfolio businesses, innovation projects and clinical studies.



There are no upcoming events at this time.


Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.

Clinical studies

Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.

Key figures 2010 – 2020

# Ideas evaulated (DOFI)

# Companies established

# Licence agreements

# New patent applications

MNOK transferred back to research, innovation and inventors

# Clinical Trials managed

Portfolio businesses

Portfolio businesses

Inven2 has a portfolio comprising 53 companies. We have established them either on our own or alongside investors to commercialise research results from innovative researchers. The point of departure for the companies are research results from innovative researchers. The portfolio value in October 2020 is NOK 23 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.

Products on the market

Products on the market

Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.